✦ LIBER ✦

Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC

✍ Scribed by Stephanie L. Hines; Betty Mincey; Todor Dentchev; Jeff A. Sloan; Edith A. Perez; David B. Johnson; Paul L. Schaefer; Steve Alberts; Heshan Liu; Stephen Kahanic; Miroslaw A. Mazurczak; Daniel A. Nikcevich; Charles L. Loprinzi

Publisher: Springer US
Year: 2009
Tongue: English
Weight: 190 KB
Volume: 117
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-009-0332-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effective inhibition of aromatase inhibi

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole : ZO-FAST study results

✍ Nigel J. Bundred; Ian D. Campbell; Neville Davidson; Richard H. DeBoer; Holger E 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

## Abstract ## BACKGROUND. Letrozole is safe and effective in postmenopausal women with estrogen receptor‐positive early breast cancer, but long‐term aromatase inhibitor use may cause bone loss and increase fracture risk. This study evaluated an immediate or delayed strategy of bone protection the